argenx SE | Investor Day Presentation Deck | 69 slides · page 19 of 69
The chart shows that Efgartigimod maintains FcRn volume similar to 'No treatment', whereas the 'Control anti-FcRn mAb' causes a significant reduction in volume over time.
Conference presentation · other · analyze_data · balanced density
Slide locked Sign in to view
Slide schematic 4/4
chart 1/1 image 1/1 legend 1/1 title 1/1
Components 4
line photo legend headline
Tools 0
∅
No tools
No canon tool match is anchored to this slide.
Metrics 0
∅
No metrics
No metric insight is anchored to this slide.
Frameworks 0
∅
No frameworks
No framework match is anchored to this slide.